For the treatment of acute myeloid leukemia (AML), AMG 330, a CD33/CD3 BiTE® antibody construct, has shown preclinical activity and is currently undergoing phase 1 clinical testing (NCT02520427) [9, 10]. This evidence concerns the gene CD33 and acute myeloid leukemia.